1314971-25-9

Upstream product

• 491-19-0 1,4-anhydro-D-ribitol 
• 160308-05-4 3,5-O-(1,1,3,3-tetraisopropyl-1,3-disiloxanediyl)-1-deoxy-D-ribofuranose 
• 1356682-38-6 1,4-anhydro-2-O-benzyl-3,5-O-(di-tert-butylsilanylidene)-D-ribitol 
• 1314971-06-6 (4aR,7S,7aS)-2,2-ditert-butyl-4a,6,7,7a-tetrahydro-4H-furo[3,2-d][1,3,2]dioxasilin-7-ol 
• 1356682-35-3 2-O-benzyl-1-deoxy-D-ribofuranose 
• 1356682-32-0 2-O-benzyl-1-deoxy-5-O-(4,4'-dimethoxytrityl)-D-ribofuranose 
• 124482-92-4 2-cyanoethyl-N,N-(diisopropylamino)chlorophosphine 
• 100-39-0 benzyl bromide 

Relevant academic research and scientific papers

Introduction of 2-O-benzyl abasic nucleosides to the 3′-overhang regions of siRNAs greatly improves nuclease resistance

Chemically modified siRNAs containing 2-O-benzyl-1-deoxy-D-ribofuranose (RHOBn) in their 3′-overhang region were significantly more resistant towards serum nucleases than siRNAs possessing the natural nucleoside in this region. The knockdown efficacies and binding affinities of these modified siRNAs to the recombinant human Argonaute protein 2 (hAgo2) PAZ domain were comparable with that of siRNA with a thymidine dimer at the 3′-end.

Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications

It is an object of the instant invention to provide a method for the rapid evaluation of novel sugar modifications to be used in siRNA synthesis including the rapid evaluation of chemical modification patterns within the siRNA to effectuate increased stability and ultimately increased efficacy of a siRNA therapeutic. It is a further object of the instant invention to provide novel nucleosides useful for siRNA therapy.